Cel-Sci Corporation CVM

CEL-SCI Corporation released its financial results for the fiscal third quarter of 2026. Quarterly results disclose financial position and operations that can shift near-term investor sentiment.

CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit ahead of head and neck cancer confirmatory registration study. Peer-reviewed data strengthens Multikine development case ahead of pivotal registration study.

CEL-SCI Corporation reports acceptance of new Multikine Phase 3 data for publication in a leading oncology journal, highlighting overall survival benefits for underserved head and neck cancer patients. Positive Phase 3 survival data publication acceptance signals potential regulatory progress and market interest for Multikine.

CEL-SCI will launch an FDA registration-enabling Phase 3 confirmatory study of Multikine for newly diagnosed head and neck cancer to secure market approval. Phase 3 study launch advances Multikine toward regulatory approval and commercial sales in head and neck cancer.

CEL-SCI and Saudi Amarox signed a strategic agreement at BIO 2026 to advance U.S.-Saudi cooperation in cancer care. Strategic agreement with Saudi partner signals potential market expansion for cancer treatments without immediate financial details.

CEL-SCI advances Multikine immunotherapy for head and neck cancer via dual U.S. registration study and Saudi market entry strategy. Dual U.S. registration study plus Saudi entry signals major regulatory and commercial progress for Multikine.

CEL-SCI Corporation closed its offering. Closing provides CEL-SCI with fresh capital that affects its financial resources and operations.

Cel-Sci Corporation announced its second equity raise in just over a month for its cancer drug, causing CVM stock to sink in pre-market trading. Repeated equity raises dilute shareholder value and signal ongoing cash needs that pressure CVM's valuation.

CEL-SCI Corporation priced its offering. Offering pricing supplies capital while creating potential share dilution for Cel-Sci Corporation.

CEL-SCI and Saudi Amarox will hold signing ceremony at BIO 2026 for strategic agreement advancing commercialization and distribution of Multikine in Saudi Arabia. Distribution deal opens one additional market for Multikine but remains limited in geographic and revenue scope.

CEL-SCI Corporation closed its public offering, securing additional capital through share sales to fund operations. Closing the public offering provides CEL-SCI with vital funding to advance clinical trials and extend operational runway.

CEL-SCI Corporation announces pricing of its public offering to raise capital through new share sales. Public offering pricing delivers vital funding for operations and development but causes share dilution that significantly sways financial position and investor sentiment.

CEL-SCI Corporation entered a strategic agreement with Amarox for the registration, commercialization, and distribution of its Multikine immunotherapy in Saudi Arabia. Strategic deal grants access to Saudi Arabia's market for Multikine, a key product, enhancing CEL-SCI's commercialization prospects and revenue potential.

CEL-SCI Corporation reported fiscal first quarter 2026 results, highlighting key financial metrics, operational updates, and progress on its immunotherapy pipeline including Multikine. Quarterly earnings reports directly impact financial performance and investor sentiment for biotech companies like CVM.

Cel-Sci Corporation reported fiscal first-quarter results with revenue of $0 versus $30,000 last year, net loss of $6.8 million or 6 cents per share versus $5.5 million or 5 cents last year. Q1 earnings miss on revenue and wider net loss impacts financial performance and investor sentiment moderately.

Cel-Sci Corporation reported its fiscal 2025 results, highlighting advancements in its immunotherapy product, Multikine, and ongoing clinical trials. The company noted increased revenue and a reduction in net losses compared to previous years. Management expressed optimism about upcoming regulatory submissions and potential market opportunities. The financial report reflects strategic efforts to enhance product development and expand market reach. Significant advancements in product development and potential regulatory submissions could alter the company's trajectory and investor sentiment.

CEL-SCI Corporation announced its participation in the LD Micro 'Main Event' Investor Conference, scheduled for December 5-7, 2023. The company will present its latest developments and engage with investors during the event, which is a significant platform for showcasing its progress and future plans. Participation in investor conferences can enhance visibility and investor sentiment, but the immediate impact on financial performance is expected to be limited.

Cel-Sci Corporation has successfully closed a public offering, raising $10 million. The funds will be used to support the company's ongoing clinical trials and operational expenses. This offering reflects the company's efforts to secure additional capital for its innovative therapies, particularly in the field of immunotherapy. The capital raised will support ongoing clinical trials, potentially influencing future product development and market positioning.

Cel-Sci Corporation announced the pricing of a public offering of $10 million. The offering consists of 2 million shares of common stock priced at $5.00 per share. The company intends to use the proceeds for general corporate purposes, including funding its ongoing clinical trials and other operational expenses. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The public offering may provide necessary funding for ongoing clinical trials, impacting financial performance moderately.

Cel-Sci Corporation announced a proposed public offering of its common stock, intending to raise funds for general corporate purposes, including the advancement of its immunotherapy product, Multikine. The offering is expected to enhance the company's financial position and support ongoing clinical trials. The company has not disclosed the number of shares to be offered or the price range yet. The offering is subject to market conditions and other factors. The proposed public offering may provide necessary funding for clinical trials, impacting financial performance and investor sentiment.

Cel-Sci Corporation reported its financial results for the fiscal third quarter of 2025, highlighting key metrics such as revenue, expenses, and net income. The company continues to advance its clinical programs, particularly in immunotherapy, and remains focused on its strategic goals. Management provided insights into ongoing trials and future expectations, indicating a commitment to innovation and market growth. The financial results and ongoing clinical programs may moderately influence investor sentiment and the company's competitive positioning.

Cel-Sci Corporation reported its fiscal Q3 earnings, highlighting key financial metrics and operational updates. The company continues to advance its immunotherapy product, with ongoing clinical trials and regulatory efforts. Financial results showed fluctuations in revenue and expenses, reflecting the company's investment in research and development. The outlook remains focused on upcoming milestones and potential market opportunities. The financial performance and ongoing clinical trials may moderately influence investor sentiment and operational focus.

Cel-Sci Corporation has filed for Breakthrough Medicine Designation for its Multikine immunotherapy for head and neck cancer in Saudi Arabia. This designation allows for patient access and reimbursement/sale upon approval, which is expected within approximately 60 days based on the Saudi Food and Drug Authority's timeline. The Breakthrough Medicine Designation could significantly enhance market access and revenue potential for Cel-Sci's Multikine therapy.

Cel-Sci Corporation has successfully closed a $5.7 million offering priced at-the-market under NYSE American rules. The funds raised will support the company's ongoing operations and development efforts, particularly in advancing its immunotherapy treatments. The offering provides necessary funding for ongoing operations and development, which may moderately influence the company's financial performance.

Cel-Sci Corporation is set to sign a partnership agreement with a leading pharmaceutical company in Saudi Arabia to advance the development of Multikine, a treatment for head and neck cancer. This collaboration aims to enhance the reach and effectiveness of Multikine in the region, potentially improving treatment options for patients suffering from this type of cancer. The partnership with a prominent Saudi Arabian pharma company is likely to significantly enhance market access and development for Multikine, impacting Cel-Sci's future performance.

CEL-SCI Corporation announced a best-efforts offering of 1,500,000 shares of common stock at $3.82 per share, aiming for gross proceeds of approximately $5.7 million. The offering is set to close on July 14, 2025, pending customary conditions. Proceeds will fund the development of Multikine, general corporate purposes, and working capital. ThinkEquity is the sole placement agent, and the offering is made under a shelf registration statement filed with the SEC. Multikine is designed to enhance the immune response in cancer patients and has received Orphan Drug designation from the FDA for specific cancer treatments. The offering may provide necessary funding for the development of Multikine, impacting financial performance and product innovation.

CEL-SCI Corporation commended the FDA's approval of Merck's Keytruda for treating PD-L1 positive head and neck cancer, highlighting a favorable comparison with its own Multikine therapy. Multikine demonstrated a 66% reduction in death risk for patients with low to zero PD-L1, while Keytruda showed only a 30% reduction in recurrence without improving overall survival. CEL-SCI has received FDA approval for a confirmatory study involving 212 patients, suggesting potential for accelerated approval based on Multikine's positive outcomes. The company aims to enhance immune response before surgery to improve survival rates. Keytruda's approval and the positive results from Multikine's study indicate significant potential for CEL-SCI's future product development and market positioning.

CEL-SCI Corporation announced the closing of its public offering of 2,000,000 shares of common stock at $2.50 per share, raising $5,000,000 in gross proceeds. The company plans to use the net proceeds for the development of Multikine, general corporate purposes, and working capital. The underwriters have a 45-day option to purchase an additional 190,000 shares. The offering was conducted under a shelf registration statement filed with the SEC. Multikine is an investigational therapy designed to enhance the immune response in cancer patients and has received Orphan Drug designation from the FDA for head and neck cancer treatment. The public offering and funding for Multikine's development are significant strategic moves that could enhance CEL-SCI's market position and investor sentiment.

CEL-SCI Corporation announced a public offering of 2,000,000 shares of common stock at $2.50 per share, aiming to raise $5,000,000 before expenses. The underwriters have a 45-day option to purchase an additional 190,000 shares. Proceeds will fund the development of Multikine and general corporate purposes. The offering is set to close on May 23, 2025, pending customary conditions. CEL-SCI's Multikine is an investigational therapy for head and neck cancer, having received Orphan Drug designation from the FDA. The company has operations in Virginia and Maryland. The public offering and funding for Multikine's development are significant strategic moves that could enhance the company's market position.

CEL-SCI Corporation announced a proposed underwritten public offering of its common stock and/or pre-funded warrants, with proceeds intended for the development of Multikine, general corporate purposes, and working capital. The offering is subject to market conditions and will be conducted under a shelf registration statement filed with the SEC. A preliminary prospectus supplement will be available for interested parties. Multikine, designed to enhance the immune response in cancer patients, has received Orphan Drug designation from the FDA and is set to undergo a confirmatory Registration Study for head and neck cancer. The proposed public offering and ongoing development of Multikine could significantly impact the company's financial performance and market positioning.